Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carfilzomib
Drug ID BADD_D00367
Description Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Indications and Usage Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.[L39392]
Marketing Status approved; investigational
ATC Code L01XG02
DrugBank ID DB08889
KEGG ID D08880
MeSH ID C524865
PubChem ID 11556711
TTD Drug ID D00UVA
NDC Product Code 76055-0035; 76075-103; 76075-101; 63552-009; 67262-0010; 42385-731; 76075-102; 63552-035; 54893-0037; 52076-6251; 55111-985; 11722-059
UNII 72X6E3J5AR
Synonyms carfilzomib | PR-171 | PR171 | Kyprolis
Chemical Information
Molecular Formula C40H57N5O7
CAS Registry Number 868540-17-4
SMILES CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3) NC(=O)CN4CCOCC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bone neoplasm16.29.01.001; 15.09.02.0010.000168%Not Available
Bone pain15.02.01.0010.002653%
Burning sensation17.02.06.001; 08.01.09.0290.001500%Not Available
Capillary leak syndrome24.06.03.001; 08.01.07.0120.000168%
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.0010.004421%
Cardiac failure acute02.05.01.0050.000392%Not Available
Cardiac failure congestive02.05.01.0020.002350%Not Available
Cardiac hypertrophy02.04.02.0170.000112%Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000672%Not Available
Cardiogenic shock02.05.01.003; 24.06.02.0060.000224%Not Available
Cardiomegaly02.04.02.0010.000392%Not Available
Cardiomyopathy02.04.01.0010.000895%Not Available
Cardiovascular disorder02.11.01.010; 24.03.02.0090.001130%Not Available
Cataract06.06.01.0010.000716%
Cerebral ischaemia24.04.06.003; 17.08.01.0050.000168%
Cerebral thrombosis24.01.04.003; 17.08.01.0060.000112%Not Available
Chest discomfort02.02.02.009; 22.12.02.002; 08.01.08.0190.001914%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.005283%Not Available
Chills15.05.03.016; 08.01.09.0010.004242%
Choking22.12.03.0030.000168%Not Available
Coccydynia15.02.01.0040.000112%Not Available
Cold sweat23.02.03.002; 08.01.03.0240.000381%Not Available
Confusional state19.13.01.001; 17.02.03.0050.004231%
Constipation07.02.02.001--
Coronary artery disease02.02.01.001; 24.04.04.0060.000224%Not Available
Cough22.02.03.0010.005697%
Death08.04.01.0010.030948%
Decreased immune responsiveness10.02.01.0410.000280%Not Available
Decubitus ulcer23.03.11.0060.000112%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 12 Pages